Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - June 2016

The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of June 2016. This month there are two technology appraisals that impact upon primary care.

The Alirocumab technology appraisal recommends this treatment as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia only if low‑density lipoprotein concentrations are persistently above the thresholds specified in the appraisal and the manufacturer provides alirocumab with the discount agreed in the patient access scheme.

The Evolocumab technology appraisal recommends this treatment as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia provided the dosage is 140 mg every 2 weeks and only if low‑density lipoprotein concentrations are persistently above the thresholds specified in the appraisal and the manufacturer provides evolocumab with the discount agreed in the patient access scheme.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - June 2016' on Email Share 'NICE Guidance - June 2016' on Delicious Share 'NICE Guidance - June 2016' on Digg Share 'NICE Guidance - June 2016' on Facebook Share 'NICE Guidance - June 2016' on Google+ Share 'NICE Guidance - June 2016' on reddit Share 'NICE Guidance - June 2016' on StumbleUpon Share 'NICE Guidance - June 2016' on Twitter

atomic-wealth

No Comments to “NICE Guidance - June 2016”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,523 spam comments.

atomic-wealth
fond-illness
summer